Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Assets: 2013-2025

Historic Current Assets for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $461.0 million.

  • Coherus Oncology's Current Assets rose 24.91% to $461.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.0 million, marking a year-over-year increase of 24.91%. This contributed to the annual value of $341.6 million for FY2024, which is 28.18% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Current Assets is $461.0 million, which was up 21.24% from $380.2 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Current Assets high stood at $673.0 million for Q3 2021, and its period low was $310.2 million during Q1 2025.
  • Over the past 3 years, Coherus Oncology's median Current Assets value was $385.5 million (recorded in 2023), while the average stood at $424.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 98.62% in 2024, then plummeted by 50.57% in 2025.
  • Coherus Oncology's Current Assets (Quarterly) stood at $602.3 million in 2021, then tumbled by 36.71% to $381.2 million in 2022, then grew by 24.76% to $475.6 million in 2023, then dropped by 28.18% to $341.6 million in 2024, then grew by 24.91% to $461.0 million in 2025.
  • Its last three reported values are $461.0 million in Q3 2025, $380.2 million for Q2 2025, and $310.2 million during Q1 2025.